About 17 million people die each year from cardiovascular diseases (CVDs), a number that is expected to grow to more than 23 million by 2030. Of these deaths, an estimated 7.4 million were due to heart disease, including heart valve disease (HVD) such as tricuspid regurgitation (TR). The golden standard methods for tricuspid valve diseases are standard open-heart surgery and transcatheter valve replacement. However, such high-risk interventions require a long recovery period associated with lengthy hospitalization and there is significant hospital mortality (more than 10%). Transcatheter tricuspid valve replacement (TTVR) is still ineffective due to the increased risk of side effects in the right ventricle (RV) hence it’s still a way off from market adoption.
The TriSol System is a heart valve replacement system for treating severe TR and preventing RV dysfunction which usually follows tricuspid valve surgery. A flexible delivery system allows the valve to be positioned into the heart through support arms for anchoring to the tricuspid physiological site. The entire procedure takes up to 30 minutes compared to 2-4 hours of standard surgery. The Trisol System will allow cardiologists to perform a quick and safe implant procedure thus increasing the number of treated patients and reducing in-hospital and recovery time. Moreover, it will increase heart performance and reduce the risk of mortality typical of open-heart surgeries.